The seminar will be held in Uppsala on Monday 2 September 2019, at 15:15 at BMC Uppsala
in Stockholm on Tuesday 3 September 2019, at 15:00 in Gamma 2- lunchroom, SciLifeLab Campus Solna
Dr. Kim D. Janda has been the Ely R. Callaway, Jr. Chaired Professor in the Departments of Chemistry, Immunology and Microbial Science at The Scripps Research Institute (TSRI) since 1996 and has been the Director of the Worm Institute of Research and Medicine (WIRM) at The Scripps Research Institute since 2005. He received B.S. degree in Clinical Chemistry from University of South Florida, M.S. from University of Arizona and holds a Ph.D. degree from the University of Arizona with Robert B. Bates in natural product total synthesis. He is considered one of the first scientists to merge chemical and biological approaches into a cohesive research program and is well known for his bridging of the fields of chemistry and immunology. Working at this interface he has shown how antibodies could be transformed from simple binding entities to catalysts. He pioneered treating drug addiction through immunopharmacotherapy, the creation of synthetic diversity methods, including phage display, and small molecule DNA encoding methodologies. He has published over 550 peer-reviewed publications, an h-index of 73 and is an associate editor of “Bioorganic & Medicinal Chemistry” since 2008. He founded the biotechnological companies CombiChem, Drug Abuse Sciences and AIPartia and is an inventor on multiple patents in the life sciences industry.
Substance use disorders are a global public health concern with less than optimal treatment outcomes. This is most evident with the national emergency declared against the opioid crisis. Our ability to prevent the spread of drug abuse and aid individuals with a substance use disorder is handicapped by the lack of sufficient treatment modalities. For example, many patients receiving treatment relapse; therefore, there is an urgent need to discover effective medications to treat opioid abuse. Traditional, small-molecule approaches have only been marginally successful in treating substance use disorders; as such we have sought alternative treatments to conventional drug pharmacotherapies. “Biologics” based therapeutics offer an alternative to customary pharmacodynamic approaches for treating both substance use disorders as well as lethality threats from many of these drugs. Specifically, I will discuss the history and some basic tenets on vaccination as well as how vaccination can alter the pharmacokinetic properties of drugs without burdening the recipient with untoward CNS side effects. Moreover, the lecture will detail the chemistry, immunology and behavioral findings from some of our vaccines against opioids including heroin, the fentanyl’s and oxy/hydrocodone. Finally, I will detail how we can utilize a biologic from a bacterial source as a means of treating nicotine substance disorders and poisoning.
Host: Daniel Globisch, email@example.com.
Read more about Kim Janda´s research:
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.